Tesamorelin + Ipamorelin
aka Tesa/Ipa
Mechanism
Pre-mixed blend of Tesamorelin (a stabilized GHRH(1-44) analog) and Ipamorelin (a selective ghrelin-receptor agonist). Tesamorelin is FDA-approved as Egrifta for HIV-associated lipodystrophy; Ipamorelin is not FDA-approved. The blend itself is NOT clinically validated — no controlled trial has tested Tesamorelin co-administered with Ipamorelin. Evidence is inferred from the individual components.
Identification
| Typical dose | Tesamorelin 2 mg/day SC + Ipamorelin 100–300 mcg per injection SC (1–3x/day); often combined in a single injection |
|---|---|
| Half-life | Tesamorelin: ~26–38 min (SC, repeated dosing); Ipamorelin: ~2 hours |
Vendors selling Tesamorelin + Ipamorelin
| Vendor | Size | Price | Listed purity | Trust |
|---|---|---|---|---|
| Orbitrex Peptides | — | $79.99 | — | 95 |
| Peptide Tech | — | $69.99 | — | 94 |
| Skye Peptides | — | $75.00 | — | 90 |
| Peptidegurus | 8 mg | — | — | 84 |
| Cocer Peptides | — | $140.00 | — | 82 |
| Cocer Peptides | — | $220.00 | — | 82 |
| Cernum Biosciences | — | $92.99 | — | — |
| NG Peptide | — | $60.00 | — | — |
| Alpha Omega | — | $109.00 | — | — |
| Amino Sequence | 20 mg | $100.00 | — | — |
Research
Introduction Integrase strand transfer inhibitor-based regimens (eg, containing dolutegravir [DTG]) are associated with weight/body mass index (BMI) increases among people living with HIV-1 (PLWH).
source →Introduction Integrase strand transfer inhibitor (INSTI)-containing antiretroviral therapy (ART) has been associated with weight gain, though there is limited information on associations between ART-related weight gain and cardiometabolic outcomes among people living with HIV-1 (PLWH).
source →